🇯🇵 日本語 🇺🇸 English
3,817 companies 12,975 AI summaries 9,784 risk analyses 5,404 growth scores Register free — watchlist & alerts →
EDINET 3750 Negative Risk Analyzed 📈 Growth 5/10

ADR Biomedical Holdings Inc.

Semi-Annual Report - 23rd Term(2026/04/01 - 2027/03/31) ／ 2026-11-13 16:34

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

Going ConcernEarningsNew ProductCapacityDemand
AI Summary 2026-11-13 16:58

ADR Biomedical Holdings posted mid-term revenue of ¥66M (+262.7% YoY), but recorded operating loss of ¥311M and net loss of ¥224M. The company remains in pre-commercialization phase, ending the period with negative equity of ¥-202M, raising substantial going concern doubts. Insurance coverage approval for male stress urinary incontinence treatment received in August 2026; full-scale sales expected from H2 FY2027.

KEY POINTS
  • Revenue surged +262.7% to ¥66M, though operating loss narrowed from ¥332M to ¥311M
  • Negative equity of ¥-202M at mid-period end; material uncertainty regarding going concern premise
  • Insurance reimbursement approved (August 2026) for male SUI treatment; commercialization scheduled for H2 FY2027
📊 Revenue
Revenue +262.7% (¥18M → ¥66M)
💰 Operating profit
Operating loss improved -6.2% (¥-332M → ¥-311M); ordinary loss improved -9.2% (¥-347M → ¥-315M)
🔮 Outlook
FY2027 revenue, operating profit, ordinary profit and net income expected to improve significantly vs FY2026
📈 Growth outlook 📈 Growth 5/10
While revenue grew 262% in H1, persistent operating losses and negative equity limit real growth prospects. Insurance reimbursement and full-scale commercialization in FY2027 are critical growth drivers, but face execution risk. Domestic production transition and Neocella expansion offer medium-term margin improvement potential.
Growth drivers
  • Full-scale commercialization of male SUI treatment following insurance reimbursement approval (August 2026); sales ramp expected H2 FY2027
  • Completion of domestic production transition for Celution centrifuge and cell therapy kit; mass production capability established
  • Launch of Neocella (high-concentration exosome product) business as new revenue stream
  • Cost structure improvement through completion of R&D development phase
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Going Concern Uncertainty Negative equity of ¥-202M at mid-period. Persistent operating losses and negative operating cash flow. Funding requirements for FY2028+ remain unconfirmed as to method, amount and timing. 9/10
Market Risk Insurance reimbursement approval (inner notice) received, but final implementation timing and market uptake remain uncertain. Revenue plan shortfall risk if patient demand ramps slower than expected. 8/10
Shareholder Equity Deterioration Risk Shareholder equity ratio severely low at 6%, worsened from -74.3%. Limited leeway for improvement without capital raise. 8/10
Performance Deterioration Risk Operating losses persist; mid-term net loss of ¥224M. If domestic production and Neocella ramp falls short, losses could widen further. 7/10
Funding Risk Dependent on HG Capital's ¥400M debt forgiveness and ¥500M commitment line. Future funding requirements and dilution risk unclear. 7/10
Regulatory Risk Dependent on regulatory approvals for medical devices and insurance reimbursement. Risk of approval delays or significantly lower reimbursement rates. 6/10
Supply Chain Risk Domestic production transition ongoing, dependent on manufacturing partner coordination. Delays or quality issues could impede sales launch. 5/10
Competitive Risk Cell therapy market is increasingly competitive. Risk of price erosion and market share loss from existing and new competitors. 5/10
9/10 Going Concern Uncertainty
Negative equity of ¥-202M at mid-period. Persistent operating losses and negative operating cash flow. Funding requirements for FY2028+ remain unconfirmed as to method, amount and timing.
8/10 Market Risk
Insurance reimbursement approval (inner notice) received, but final implementation timing and market uptake remain uncertain. Revenue plan shortfall risk if patient demand ramps slower than expected.
8/10 Shareholder Equity Deterioration Risk
Shareholder equity ratio severely low at 6%, worsened from -74.3%. Limited leeway for improvement without capital raise.
7/10 Performance Deterioration Risk
Operating losses persist; mid-term net loss of ¥224M. If domestic production and Neocella ramp falls short, losses could widen further.
7/10 Funding Risk
Dependent on HG Capital's ¥400M debt forgiveness and ¥500M commitment line. Future funding requirements and dilution risk unclear.
6/10 Regulatory Risk
Dependent on regulatory approvals for medical devices and insurance reimbursement. Risk of approval delays or significantly lower reimbursement rates.
5/10 Supply Chain Risk
Domestic production transition ongoing, dependent on manufacturing partner coordination. Delays or quality issues could impede sales launch.
5/10 Competitive Risk
Cell therapy market is increasingly competitive. Risk of price erosion and market share loss from existing and new competitors.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login